HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 23, No 08, August 2019 – Digitalization vs Digitization — Exploring Emerging Trends in Healthcare       » Shanghai neurologists test brain implant to tackle drug addiction       » Gene-editing researchers reduce cancer risk       » Artificial Intelligence in Precision Cancer Diagnostics: Myth or Magic?       » Healing with Technology       » Smart Hospital: An Instrument of Care       » Transforming Healthcare with Data and Artificial Intelligence      
BIOBOARD
Novel nanoparticle vaccine to fight against MERS-CoV
Virus-mimicking vaccine nanotechnology makes a strong vaccine against lethal emerging viruses

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly lethal emerging disease that is transmitted from camels to humans.

Since the first identified case of MERS in 2012 in Saudi Arabia, there have been over 2000 confirmed cases across 27 countries. The disease has a high mortality rate of over 34 per cent and there is no available vaccine against the pathogen.

As one of the priority diseases identified by the World Health Organization, there is an urgent need for new vaccine technology against the pathogen.

An international consortium comprised of scientists from the University of Texas Medical Branch (UTMB), National Taiwan University, and Academia Sinica has developed a novel nanoparticle vaccine mimicking the morphology of MERS-CoV against the infectious pathogen. The nanoparticle vaccine has proven to be safe and effective against a lethal challenge of MERS-CoV in a transgenic mouse model.

Due to the highly mutational nature of many emerging diseases, effective prophylactic strategies demand multidisciplinary collaborations for innovation solutions. The nanoparticle vaccine development was supported by the National Taiwan University and Academia Sinica Innovative Joint Program and the Ministry of Science and Technology of Taiwan, and preclinical testing was performed at UTMB鈥檚 biosafety lab.

By integrating the receptor binding domain of MERS-CoV with a capsid-like polymeric nanoshell loaded with a potent immunologic stimulant, a highly potent nanoparticle vaccine can be prepared. In a mouse model, the vaccine stimulated a high and durable level of anti-MERS-CoV antibodies that can neutralise MERS-CoV antigens.

In addition, the vaccine also triggered an elevated level of antigen-specific T cells, which is critical for MERS-CoV protection. In a study with live MERS-CoV challenge, mice vaccinated with the nanoparticle vaccine showed 100 per cent survival whereas all the non-vaccinated mice succumbed to the lethal challenge.

Unlike live attenuated virus vaccines, the nanoparticle vaccine possesses superior safety and is comprised entirely of biocompatible materials. The international team aims to assess the nanoparticle vaccine in non-human primates before moving to clinical testing.

The international consortium is led by Professor Kent Tseng at the University of Texas Medical Branch, Professor Hui-Wen Chen at the National Taiwan University, and Dr. Che-Ming Jack Hu at Academia Sinica.

Their findings were published in Advanced Functional Materials.

Click here for the complete issue.

NEWS CRUNCH  
news Not Science Fiction anymore — the emergence of AI and Robotics in Healthcare
news How blockchain can save the food industry millions from recalls
news China Healthcare and Pharma Digital Innovation Summit
news BIO-PHARM2019 — The Most Influential Forum in China's Biopharm Industry
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy